Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors

The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Takeshi, Ozaki, Shuji, Oda, Asuka, Tsuji, Daisuke, Ikegame, Akishige, Iwasa, Masami, Udaka, Kengo, Fujii, Shiro, Nakamura, Shingen, Miki, Hirokazu, Kagawa, Kumiko, Kuroda, Yoshiaki, Kawai, Shigeto, Itoh, Kohji, Yamada-Okabe, Hisafumi, Matsumoto, Toshio, Abe, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873421/
https://www.ncbi.nlm.nih.gov/pubmed/24386306
http://dx.doi.org/10.1371/journal.pone.0083905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873421/
https://www.ncbi.nlm.nih.gov/pubmed/24386306
http://dx.doi.org/10.1371/journal.pone.0083905

Ejemplares similares